Evidence map›Paper›PMID 26089091›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2015

Mammary analog secretory carcinoma, low-grade salivary duct carcinoma, and mimickers: a comparative study.

Todd M Stevens, Andra O Kovalovsky, Claudia Velosa, Qiuying Shi, Qian Dai, Randall P Owen, Walter C Bell, Shi Wei, Pamela A Althof, Jennifer N Sanmann and 5 more

Erratum issuedOpen access · bronzeAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
14.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 132 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Mammaglobin negative secretory carcinoma of salivary gland--a diagnostically challenging case report.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025
    Article
  5. Review
  6. Review
  7. Review
  8. Secretory carcinoma of the salivary gland is rich in lactoferrin: a possible lactational-like differentiation?European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Canalicular adenoma with unicystic morphology. A rare entity.Journal of clinical and experimental dentistry · 2021
    Article
  16. Review
  17. Article
  18. Characterization of novel genetic alterations in salivary gland secretory carcinoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Todd M StevensDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
Andra O KovalovskyDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
Claudia VelosaDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
Qiuying ShiDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
Qian DaiDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
Randall P OwenDepartment of Surgery, Mount Sinai Hospital, Icahn School of Medicine, New York, NY, USA.
Walter C BellDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
Shi WeiDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
Pamela A AlthofHuman Genetics Laboratory, Munroe-Meyer Institute, University of Nebraska Medical Center, Omaha, NE, USA.
Jennifer N SanmannHuman Genetics Laboratory, Munroe-Meyer Institute, University of Nebraska Medical Center, Omaha, NE, USA.ORCID 000000034576025X
Larissa SweenyDepartment of Surgery, Division of Otolaryngology, Head and Neck Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
William R CarrollDepartment of Surgery, Division of Otolaryngology, Head and Neck Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Gene P SiegalDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
Martin J BullockDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Margaret Brandwein-GenslerDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
University of Alabama at Birmingham · USNebraska Medical Center · USDalhousie University · CAMount Sinai Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mammary analog secretory carcinoma (MASC) is a recently recognized low-grade salivary carcinoma characterized by a specific ETV6 rearrangement. We describe 14 new MASCs and examine their immunophenotypic and genetic profiles in the context of look-alikes, namely, low-and high-grade salivary duct carcinoma and acinic cell carcinoma. ETV6 rearrangement, and robust expression of mammaglobin and S100, were demonstrated in 11/11, 14/14, and 12/14 MASCs, respectively. All low-grade salivary duct carcinomas coexpressed S100/mammaglobin (6/6); none harbored ETV6 rearrangements (0/5). Given that S100/mammaglobin coexpression and absence of zymogen granules are features of both MASC and low-grade salivary duct carcinoma, these two are best distinguished histologically. The former is predominantly an extraductal neoplasm with bubbly pink cytoplasm, whereas the latter is a distinct intraductal micropapillary and cribriform process. Querying ETV6 gene status may be necessary for difficult cases. No acinic cell carcinoma expressed mammaglobin (0/13) or harbored an ETV6 rearrangement (0/7); only 1/13 acinic cell carcinomas weakly expressed S100. DOG1 expression was limited or absent among all tumor types, except acinic cell carcinoma which expressed DOG1 diffusely in a canalicular pattern. Therefore, histology and immunohistochemistry (mammaglobin, S100, DOG1) suffices in distinguishing acinic cell carcinoma from both MASC and low-grade salivary duct carcinoma. HER2 (ERBB2) amplification was detected in only 1/10 acinic cell carcinomas, but none of the MASCs or low-grade salivary duct carcinomas tested. High-grade salivary duct carcinomas frequently expressed mammaglobin (11/18) and harbored HER2 amplifications (13/15); none harbored ETV6 rearrangements (0/12). High-grade salivary duct carcinomas can easily be distinguished from these other entities by histology and HER2 amplification.

Indexed as

AdultAgedAged, 80 and overAnoctamin-1Biomarkers, TumorChloride ChannelsDiagnosis, DifferentialErb-b2 Receptor Tyrosine KinasesETS Translocation Variant 6 ProteinFemaleGene AmplificationGene RearrangementHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMaleANO1 protein, humanAnoctamin-1Biomarkers, TumorChloride ChannelsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesETS Translocation Variant 6 ProteinNeoplasm ProteinsProto-Oncogene Proteins c-etsRepressor ProteinsS100 ProteinsSecretoglobins

Identifiers

PMID26089091
OpenAlexW578787621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.